MEDICAL RISK CLASSIFICATION FOR SEVERE COVID-19 BASED ON CHRONIC MEDICAL CONDITIONS: A COMPARATIVE ANALYSIS

4452 words

Ilse Westerhof[1*], Annemarijn de Boer[1], Angela Lupattelli[2], Isabel Slurink[1], Otilia Boldea[3], Hedvig Marie Egeland Nordeng[2,4], Jizzo R. Bosdriesz[5,6,7,8], Frank Pijpers[9,10], Maarten Schim van der Loeff[6,7,8], Mirjam Knol[5], Janneke van de Wijgert[1,5], Patricia Bruijning[1], and Ganna Rozhnova[1,11,12,13]

[1]Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
[2] Pharmacoepidemiology and Drug Safety Research group, Department of Pharmacy, University of Oslo, Oslo, Norway
[3]Department of Econometrics and OR, Tilburg School of Economics and Management, Tilburg University, Tilburg, The Netherlands
[4] Department of Child Health and Development, National Institute of Public Health, Oslo, Norway
[5]Department of Infectious Disease Control, National Institute for Diseases, Public Health and the Environment, Bilthoven
[6]Amsterdam UMC location University of Amsterdam, Infectious Diseases, Meibergdreef 9, Amsterdam, the Netherlands
[7]Amsterdam Institute for Immunology & Infectious Diseases, Amsterdam, the Netherlands
[8]Department of Infectious Diseases, Public Health Service (GGD) of Amsterdam, Amsterdam, Netherlands.
[9]Statistics Netherlands, The Hague, Netherlands
[10]Korteweg-de Vries Institute for Mathematics, University of Amsterdam, Amsterdam, The Netherlands
[11]Center for Complex Systems Studies (CCSS), Utrecht University, Utrecht, The Netherlands
[12]BioISI—Biosystems & Integrative Sciences Institute, Faculdade de Ciências, University of Lisbon, Lisbon, Portugal
[13]Faculdade de Ciências, University of Lisbon, Lisbon, Portugal
[*] Corresponding author: Ilse Westerhof; i.westerhof-4@ucmutrecht.nl

Abstract (299 words)

Background: The European Centre for Disease Prevention and Control provides listings of medical conditions conferring high- or moderate-risk for severe COVID-19. Additionally, individual European countries developed national risk classifications to guide COVID-19 vaccination recommendations.

Methods: This multi-country healthcare data-linkage study included 17.4 million inhabitants in the Netherlands and 5.6 million inhabitants in Norway in 2020. Medical conditions were defined using ICD-10 codes in the European and Dutch classifications, and ICD-10 and ICPC-2 codes in the Norwegian classification. Subjects were classified as high-, moderate-, or low-risk.

Findings: Discordance between European and national classification was 12.0% and 13.8% in the general population, 36.5% and 38.2% among hospitalized individuals, and 46.6% and 45.1% deceased individuals, in the Netherlands and Norway, respectively. The European classification assigned more individuals to high-risk, while national classifications assigned more individuals to moderate-risk. Classification discordances most frequently involved subjects with cardiovascular disease, lung disease, and diabetes mellitus.

Interpretation: The European classification defines a substantially larger proportion of the population as high-risk for severe COVID-19 compared to national classifications. This may have implications for post-pandemic vaccination programs. Further research should assess to what extent the discordant medical conditions determine the risk of developing severe COVID-19.

Funding: ZonMw, EU, FCT, Norwegian Research Council's COVID-19 Emergency Call, iAPOGEE.

Key words: Severe COVID-19 | Chronic medical conditions | Medical risk classification

53 # Introduction

54 The impact of public health measures, including COVID-19 vaccination, depends on the
55 accurate identification of populations at elevated risk for severe outcomes, including
56 hospitalization and death [1]. The World Health Organization recommends targeting
57 vaccination programs to population groups at the highest risk of severe COVID-19 [1], but
58 disparities exist in the risk classifications developed by different health authorities. While
59 COVID-19 currently presents as common cold- or flu-like illness, older individuals and those
60 with certain chronic medical conditions still face higher hospitalization and death rates
61 compared to the general population [2,3]. Most risk classifications group individuals into
62 high-, moderate-, and low-risk for severe COVID-19, based on factors like medical
63 conditions and age. High-risk individuals have chronic conditions that lead to a much higher
64 likelihood of severe outcomes, while those in the moderate-risk group face an elevated but
65 lower risk.
66
67 Informed by influenza risk classifications and studies on risk factors for severe COVID-19,
68 national (e.g., the Health Council of the Netherlands[4] and the Public Health Institute in
69 Norway [5]) and international (e.g., the European Centre for Disease Prevention and Control
70 [6]) public health authorities assigned high- or moderate-risk of developing severe COVID-
71 19 to specific pre-existing medical conditions. These medical risk classifications have
72 remained unchanged [6,7] or undergone minor alterations [4,5,8,9] since their development at
73 the beginning of the pandemic. They have continued to guide epidemiological research and
74 policy decisions on eligibility criteria and prioritization for vaccination programs aimed at
75 reducing the incidence of severe COVID-19. While these European and national

classifications can be applied within the same country, it is unclear to what extent they differ in assigning medical risk status to individuals.

To inform evidence-based decision-making for severe COVID-19, we conducted a comparative analysis of risk status in the respective national versus the European classification. This observational national registry-based cohort study used Dutch and Norwegian health and administrative data from 1 January 2020, linked at the individual level, including 17.4 million inhabitants of the Netherlands and 5.6 million inhabitants of Norway. We aimed to examine discordance between the respective national and European medical risk classifications for severe COVID-19 for the Netherlands and Norway across general, hospitalized, and deceased populations, and investigate related factors.

Methods

Data Collection

Data collection – The Netherlands

The Dutch dataset included hospital discharge registry (DHD) data for all inhabitants of the Netherlands as per the Dutch Population Registry on 1 January 2020, as well as individuals hospitalized and deceased due to COVID-19 in 2020. The two registries were linked using unique personal identification numbers. The Population Registry was used to extract age, immigration, and emigration dates. The DHD provided information on chronic medical conditions diagnosed in hospitals since 1 January 1995, including the date of diagnosis. All diagnoses were registered according to the International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10) [10].

Data collection – Norway

The Norwegian dataset included data from multiple Norwegian registries for all inhabitants of Norway as per the National Population Registry on 1 January 2020, as well as individuals hospitalized and deceased due to COVID-19 in 2020. The registries included the Statistics Norway (SSB) registry, the Norwegian Patient Registry (NPR), and Norway Control and Payment of Health Reimbursements (KUHR) registry, and the Norwegian Cause of Death Registry (DAR). These registries were linked using unique personal identification numbers. The NPR and SSB registries were used to extract age, immigration, and emigration dates for all inhabitants of Norway. The KUHR registry provided information on medical diagnoses in primary and secondary outpatient care using the International Classification of Primary Care (ICPC-2/ICPC-2B) and ICD-10 codes, respectively [10,11]. The NPR provided information on medical diagnoses in specialist outpatient and inpatient care, using ICD-10 coding. Both

111 KUHR and NPR provided medical diagnosis data since 1 January 2010. DAR provided
112 information on mortality.
113

114 Definitions of severe COVID-19

115 **COVID-19 Hospitalization** was defined as hospital admission for at least 24 hours and i) a
116 primary diagnosis with ICD-10 code U071, U072, or U109; or ii) a secondary diagnosis with
117 ICD-10 code U071, U072, or U109 combined with a primary code of respiratory illness
118 (defined as any of the ICD-10 J-codes). This definition was based on prior research in
119 Norway [12].
120
121 **Death due to COVID-19** was defined as individuals with either i) COVID-19 listed as the
122 primary cause of death (ICD-10 codes U071, U072, or U109 or ii) with a COVID-19
123 hospitalization in the 7 days preceding date of death. In the Dutch data registry, only the
124 second definition was used, because cause of death was not available in death registry.
125

126 Risk classifications for severe COVID-19

127 **The Dutch risk classification** was obtained from the 'Adviesnota Vaststelling volwassen
128 medische risicogroepen COVID-19-vaccinatiecampagne' ['Recommendation on establishing
129 adult medical risk groups for the COVID-19 vaccination campaign'] in February 2023 [4].
130 This classification contains a list of chronic medical condition categories defined as either
131 high- or moderate-risk for severe COVID-19. Each medical condition was independently
132 coded using ICD-10 by two authors (AvB and IW), with no discrepancies found.
133

134 **The Norwegian risk classification** was obtained from the Norwegian Health Institute in July
135 2023 [5]. This scheme includes chronic medical condition categories with corresponding
136 ICPC-2 and ICD-10 codes classified as either high-risk or increased-risk, which we renamed
137 as high- and moderate-risk for consistency with other classifications.
138
139 **The European risk classification** was obtained from the 'Core protocol for ECDC studies of
140 COVID-19 vaccine effectiveness against hospitalization with Severe Acute Respiratory
141 Infection (SARI), laboratory-confirmed with SARS-CoV-2 or with seasonal influenza –
142 Version 3.0' dated February 2024 [6]. This protocol provides ICD-10 codes for medical
143 condition categories that are mandatory or optional for reporting in the ECDC studies. We
144 classified the former medical condition categories as high-risk and the latter as moderate-risk.
145
146 Individuals in the Dutch or Norwegian datasets were assigned to have moderate- or high-risk
147 chronic medical conditions if at least one relevant ICD-10 (both datasets) or ICPC-2 code
148 (Norwegian cohort only) was recorded for that individual within the six months prior to 1
149 January 2020. For cancer diagnoses, records within five years prior to 1 January 2020 were
150 used. These timeframes were defined according to the criteria specified in the classifications.
151 Different medical risk classifications may use different codes for the same chronic medical
152 condition, as each classification was developed with its own coding system. The ICD-10 and
153 ICPC-2 codes used for this analysis are detailed in **Supplementary Tables 1-3**.
154
155 Individuals with one or more high-risk chronic medical condition categories, regardless of
156 whether they also had one or more moderate-risk conditions, were defined as being at high-
157 risk for severe COVID-19. Individuals with one or more moderate-risk chronic medical
158 condition categories and no high-risk chronic medical condition were defined as being at

159 moderate-risk for severe COVID-19. Individuals without any listed chronic medical
160 condition categories were defined as low-risk. Pregnancy was not considered a criterion for
161 categorizing individuals into the high- or moderate-risk groups in all classifications.
162

163 Statistical Analysis

164 Data for the Netherlands and Norway were analyzed separately. Descriptive analyses were
165 performed to compare the respective national with the ECDC classification. The prevalence
166 of high- and moderate-risk medical condition categories, and the most frequent combinations
167 of medical condition categories, were shown in upset plots which visualize co-occurance of
168 chronic medical condition categories in the population. Due to privacy reasons, numbers
169 below 10 for the Dutch data and below 5 for the Norwegian data were not shown.
170

171 We reported both absolute numbers and proportions of individuals by 10-year age groups,
172 classified into high-, moderate-, and low-risk groups for severe COVID-19. The discordance
173 between the European and each national classification was calculated as the proportion of the
174 population with a different European versus national risk status and visualized with matrix
175 plots. Moreover, to understand the difference between the Dutch and Norwegian
176 classifications, discordance was also calculated for the hospitalized and deceased populations
177 in Norway. Different medical risk classifications may use different codes for the same
178 chronic medical condition because they were formulated as such by the classifications. The
179 95% confidence intervals (CI) of discordance and concordance proportions were calculated
180 using the Clopper-Pearson method [13].
181 To understand the factors related to discordance, we visualized the co-occurance of chronic
182 medical condition categories in the discordant general, hospitalized, and deceased

populations with upset plots. Also, to understand how coding differences affect overall discordance, we reviewed the most prevalent diseases in hospitalized and deceased populations one by one by assessing the differences in population sizes between classifications. Since the Netherlands and Norway consider individuals above a certain age as high-risk for severe COVID-19, we also assessed the discordance in the general population in three scenarios: 1) the entire population regardless of age, 2) individuals younger than 60 years of age, aligning with the Dutch schemes [14], and 3) individuals younger than 65 years of age, aligning with the Norwegian schemes [5].

A sensitivity analysis was conducted to assess the importance of the reference date by evaluating the discordance in the general population for 1 January 2018, 1 January 2019, and 1 January 2021, instead of 1 January 2020.

Code Availability

The codes reproducing the results of this study are publicly available at https://github.com/IWesterhof/COVID-19-risk-classifications.

Data Availability

The aggregated tables of counts generated and analyzed in this study are publicly available at https://github.com/IWesterhof/COVID-19-risk-classifications.
Results are based on calculations by the authors using non-public microdata from Statistics Netherlands. Under certain conditions, these microdata are accessible for statistical and scientific research. For further information: microdata@cbs.nl.

Ethics

The analyses conducted with data from the Netherlands did not fall under the scope of the Dutch Medical Research Involving Human Subjects Act (WMO) and, therefore, did not require approval from an accredited ethics committee in the Netherlands. For the analyses conducted with data from Norway, the Regional Committee for Medical and Health Ethics of South/East Norway (no. 285687) approved the study. The Norwegian Data Protection Services for research and the University of Oslo approved the Data Protection Impact Assessment – DPIA (no. 341884).

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

The Dutch cohort contained records of 17.4 million individuals (median age 42, interquartile range (IQR) 22-60), while the Norwegian cohort contained records of 5.6 million individuals (median age 39, IQR 21-57).

226 ## Comparison of risk classifications for severe COVID-19

227 Chronic medical condition categories included in the European, Dutch, and Norwegian risk
228 classifications and their respective risk groups for severe COVID-19 are shown in **Table 1**.
229 Several chronic medical condition categories were consistently considered high-risk (e.g.,
230 cancer, immunodeficiency, and organ transplants) and moderate-risk (e.g., dementia) in the
231 European and national classifications. There was some variability in the risk classifications of
232 other conditions. Obesity was considered high-risk in the European classification but
233 moderate-risk in both national classifications; lung disease, cardiovascular disease, and
234 diabetes mellitus were considered high-risk in the European classification but moderate-risk
235 in both national classifications. Hypertension was only listed in the European classification.
236 Down syndrome and neurological disorders with impaired breathing were not included in the
237 European classification but were considered high-risk in both national classifications.
238

239 ## Classification of the general population by risk for severe COVID-19

240 Based on the national classifications, the most prevalent chronic medical condition categories
241 in the Netherlands were lung disease, followed by cardiovascular disease, reduced immunity,
242 and neurological/-muscular disorder; all classified as moderate-risk (**Figure 1 A**). In Norway,
243 the most prevalent conditions were cardiovascular disease, lung disease, and diabetes
244 mellitus; these were also classified as moderate-risk (**Figure 1 B**). Based on the European
245 classification, the most prevalent chronic medical condition categories in the Netherlands
246 were cardiovascular disease, hypertension, and cancer, and in Norway cardiovascular disease,
247 diabetes mellitus, and cancer; all classified as high-risk (**Figure 1 C-D**). Differences in the
248 prevalence between classifications arise from variations in the diagnosis codes to define a
249 specific medical risk condition. For example, in the Netherlands, 0.54% of the population

250 **Table 1. Comparison of European and national risk classifications for severe COVID-19.** Chronic
251 medical condition categories based on ICD-10 and ICPC-2 codes (see **Supplementary Tables 1-3)** and
252 their respective risk groups for severe COVID-19 are shown. Different medical risk classifications may use
253 different codes for the same chronic medical condition.

Chronic medical condition categories	Classification		
	European	Dutch	Norwegian
Cancer (solid organ and haematological)	High	High	High
Immunodeficiency	High	High	High
Organ transplant	High	High	High
Overweight and obesity	High	High	Moderate
Lung disease	High	Moderate	Moderate
Cardiovascular disease	High	Moderate	Moderate
Diabetes mellitus	High	Moderate	Moderate
Hypertension	High	low	low
Kidney disease dialysis required	Moderate	High	High
Anaemia	Moderate	High	low
Kidney disease	Moderate	Moderate	High
Liver disease/cirrhosis	Moderate	Moderate	High
Neurological/muscular disorder (without impaired breathing)	Moderate	Moderate	High
Dementia	Moderate	Moderate	Moderate
Tuberculosis	Moderate	Moderate	low
Stroke	Moderate	low	Moderate
Asplenia	Moderate	low	low
Rheumatologic disease	Moderate	low	low
Sickle cell disease	low	High	low
Down syndrome	low	High	High
Neurological disorder with impaired breathing	low	High	High
Reduced immunity	low	Moderate	Moderate
HIV infection	low	Moderate	low
Cochlear implants	low	Moderate	low

Risk due to chronic medical conditions = High = Moderate = low

254

255

256

257 was classified as having cancer using the national classification, compared to 2.0% using the
258 European classification because this classification included seven additional ICD-10 codes
259 (**Supplementary Tables 1-2**). In Norway, 2.3% of the population was classified as having
260 cancer using the national classification compared to 2.1% using the European classification
261 due to differences in included codes.

262

In both countries and across all classifications, most individuals under 80 years of age were assigned low-risk for developing severe COVID-19 (**Figure 2**). Among children and adolescents (under 20 years old), 92.8% were classified as low-risk, 6.9% as moderate-risk, and 0.3% as high-risk, according to national schemes, while this was 98.5%, 0.4%, and 1.2%, respectively, according to the European classification. In Norway, the national classification identified 98.5% as low-risk, 0.4% as moderate-risk, and 1.2% as high-risk, while this was 96.4%, 0.5%, and 3.1%, respectively, according to the European classification. In both countries and across all classifications, the percentage of individuals in moderate- and high-risk groups increased with age, reaching 41.1% and 53.6% for those over 80 years in the national classifications, and 41.8% and 37.7% in the European classifications in the Netherlands and Norway, respectively.

In the Netherlands and Norway, risk classification differed for 12.0% and 13.8% of the general population, respectively, between the national and the European classification schemes (**Figure 3 A-B**). The European classification assigned more people as high-risk (9% in the Netherlands, 9.2% in Norway) compared to national classifications (1.5% and 3.0%, respectively). Conversely, the national classifications identified more people as moderate-risk (11.3% and 12.7%, respectively) than the European classification (1.0% and 1.3%, respectively). According to the national classifications, 87.2% of the population in the Netherlands and 84.4% in Norway were classified as low-risk. These percentages were slightly higher using the European classification (90.1% and 89.5%, respectively).

Discordance for population with severe COVID-19 in 2020

The Netherlands had 39,063 hospitalizations (median age 70 years [IQR 58-78]) and 7,031 deaths (median age 78 years [IQR 71-83]). In Norway, there were 2,228 hospitalizations (median age 64 years [IQR: 51-78]) and 514 deaths (median age 84 years [IQR: 75-90]). Cardiovascular disease, classified as high-risk in the European classification and moderate-risk in the national classifications, is the most prevalent chronic condition among hospitalized and deceased individuals (**Supplementary Figure 1-2**). Another important disease that is prevalent and differently classified is Diabetes Mellitus.

For all ages and both countries, and similar to the general population, the European classification assigns more individuals to high-risk, while national classifications define more individuals as moderate-risk (**Supplementary Figures 3-4)**. Discordance was even higher among hospitalized (the Netherlands 36.5% and Norway 38.2%), and deceased (the Netherlands 46.6% and Norway 45.1%) populations, compared to the general population (discordance in the Netherlands 12.0% and Norway 13.8%), as shown in **Figure 3C-F.** Moreover, a large part of the hospitalized (51.5% in the Netherlands and 49.5% in Norway) and deceased (40.2% and 36.2%, respectively) populations was defined as low-risk in both classifications, which means these individuals had none of the chronic medical conditions listed in classifications.

Comparison between the Norwegian and Dutch classifications for the hospitalized and deceased populations in Norway shows a discordance of 17.1% and 21.8%, respectively (**Supplementary Figure 5**). This is mainly caused by differences in selecting diseases (ICD-19 and ICPC-2 codes) within the disease categories lung disease, cardiovascular disease, and dementia.

311

312 ## Discordance between risk classifications and the related factors

313

314 Discordance was higher in elderly because the number of individuals with one or more
315 medical risk conditions was higher than in younger age groups (**Figure 3-4; Supplementary**
316 **Figure 6**). **Figure 4** shows the chronic medical condition categories in the general population
317 who were classified differently by the European and respective national classification
318 schemes (the discordant population). In the discordant population in the Netherlands, 23.5%
319 had neurological/-muscular disorders, 23.8% reduced immunity, and 13.6% kidney disease
320 according to the national classification (**Figure 4A**). In the discordant population in Norway,
321 6.7% had reduced immunity, and 2.3% neurological/muscular disorders, classified as
322 moderate- and high-risk, respectively (**Figure 4B**). On the contrary, the European
323 classification included chronic medical condition categories that were not included in the
324 national classifications. In the Netherlands, examples were hypertension and kidney disease
325 with prevalences of 25.5% and 6.3% in the discordant population. In Norway, 8.2% of the
326 discordant population had hypertension and 3.6% had kidney disease according to European
327 schemes, but not included in national schemes. Unlike Norway, none of the discordant
328 individuals in the Netherlands were classified as overweight/obese or diabetic based on the
329 European classification. Similar was observed for the hospitalized and deceased discordant
330 populations (**Supplementary Figures 7-8**).
331 Some of the discordance in the most prevalent chronic medical condition categories (lung
332 disease, cardiovascular disease, diabetes mellitus, cancer, and kidney disease) among
333 hospitalized and deceased populations may stem from differences in ICD-10 and ICPC-2
334 codes. In the Netherlands, the national classification identified more individuals with lung
335 disease and diabetes, while the Norwegian system captured more cases across all disease

336 categories except kidney disease, indicating that it includes more ICD-10 codes
337 (**Supplementary Table 4**). The European classification identified more individuals with
338 cardiovascular disease and cancer in the Netherlands and more individuals with kidney
339 disease in Norway. Notably, in the Netherlands, cancer was better captured with the
340 European classification, identifying more cases in the general (2.0% versus 0.5%),
341 hospitalized (9.1% versus 4.1%), and deceased (10.8% versus 4.1%) populations compared to
342 the Dutch classification. Similarly, in Norway, the European classification identified more
343 individuals with kidney disease in the general (0.8% versus 0.2%), hospitalized (10.1%
344 versus 2.4%), and deceased (13.3% versus 2.3%) populations compared to the national
345 classification.
346
347 In the Netherlands, the most common chronic medical condition categories varied by age
348 group (**Supplementary Figures 9-10**). In those younger than 60 or 65, lung disease was the
349 most prevalent condition, followed by neurological/-muscular disorder and cardiovascular
350 disease. In Norway, the national classification showed no differences between all ages and
351 individuals younger than 65 and 60 years of age in most pronounced chronic conditions. In
352 the Netherlands, based on the European classification there was no change in the order of
353 most prominent conditions contributing to discordance in the population aged below 60 years
354 compared to all ages. In contrast, for those aged below 65 years, the most prevalent
355 conditions were cardiovascular disease, diabetes mellitus, and lung disease, but not
356 hypertension and cancer.
357

358 ## Sensitivity analyses

359 No meaningful differences in discordance percentages were observed when using different
360 reference dates to define the study populations (data not shown).

361 # Discussion

362 In this multi-country, nationwide registry-linkage study, we compared the respective national
363 with the European medical risk classification for severe COVID-19, and classified the
364 populations of the Netherlands and Norway according to this risk, across different age
365 groups. For clarity, we reiterate that individuals with at least one high-risk chronic condition
366 were classified as high-risk, those with only moderate-risk conditions as moderate-risk, and
367 those without listed conditions as low-risk (see Methods for details). Our findings revealed
368 substantial differences between the national and European risk classifications in the general
369 population (discordance in the Netherlands 12.0% and Norway 13.8%), hospitalized patients
370 (the Netherlands 36.5% and Norway 38.2%), and deceased (the Netherlands 46.6% and
371 Norway 45.1%), with the European classification scheme assigning a broader range of
372 chronic medical condition categories to the high-risk category than the two national
373 classifications. Consequently, a larger proportion of the population is classified as high-risk
374 when using the European classification compared to the national classifications. Conversely,
375 a larger proportion of the population is classified as moderate-risk when using the respective
376 national classifications compared to the European classification. The Dutch national
377 classification may be underinclusive for cancer and cardiovascular disease, and the
378 Norwegian national classification for kidney disease, while those disease categories are
379 probably more clinically relevant as they are prevalent among hospitalized and deceased
380 populations. Interestingly, a large part of the hospitalized (51.5% in the Netherlands and
381 49.5% in Norway) and deceased (40.2% and 36.2%) populations were defined as low-risk in
382 both national and European classifications. This may be due to chronic medical conditions
383 not captured by either classification. This suggests that the classifications differ even more
384 when applied to severe COVID-19 outcomes and fail to identify a considerable share of
385 affected individuals.

These discrepancies may have implications for COVID-19 vaccination programs, which prioritize specific risk populations. Although primarily designed for research focusing on COVID-19 vaccine effectiveness and enhancing SARI surveillance in Europe, the European protocols have influenced public health policy in the past, as demonstrated, for example, with influenza vaccination strategies [15]. However, we recognize that this classification is primarily surveillance-oriented and not an officially mandated European clinical standard. While not a universal policy tool, this classification provides a structured framework that can support public health decision-making alongside other clinical and epidemiological considerations. Therefore, the European classification for severe COVID-19 could remain relevant for broader public health decisions and policy. Our comparative analysis suggests that using the European classification, 9.0% of the population in the Netherlands and 9.2% of the population in Norway are high-risk due to chronic medical condition categories and should be vaccinated, while these percentages are only 1.5% and 3.0%, respectively, when using the national classifications. Vaccination programs that prioritize both moderate- and high-risk groups, the European classification would result in 10.0% of the Dutch population and 10.5% of the Norwegian population having to be vaccinated, compared to 12.8% and 13.7%, respecitively, if using the respective national classifications. Moreover, chronic medical condition categories are defined based on different ICD-10 and ICPC-2 codes in the three classifications, resulting in differences in prevalence of individual medical risk categories across classifications. Therefore, the choice between the European or national classifications may have important consequences for vaccination prioritization and coverage, potentially influencing the impact of vaccination campaigns in preventing severe COVID-19.

410 The dominant medical condition categories generating the discordance in risk status were
411 lung and cardiovascular disease in both Norway and the Netherlands, neurological disorders
412 in the Netherlands, and diabetes in Norway. Hypertension was one of the most pronounced
413 discordant chronic condition categories between classifications. According to the European
414 classification, but not to the national ones, hypertension was considered a high-risk disorder
415 for severe COVID-19, and its prevalence estimate was 3.5% in the Netherlands and 1.4% in
416 Norway. Several studies have indicated that hypertension was not an independent predictor of
417 severe COVID-19 [16,17]. Therefore, the high-risk population might be overestimated in the
418 European classification. Lung disease, cardiovascular disease, and diabetes mellitus were also
419 among the most pronounced medical condition categories leading to discordance, which were
420 diagnosed in 1.7-4.6% of the population according to the national and European
421 classifications. These conditions were classified as moderate-risk in the national
422 classifications but as high-risk in the European classification. Although multiple studies have
423 shown an increased risk of severe COVID-19 in individuals with these medical condition
424 categories [18–20], it is unknown whether they should be part of the high- or moderate-risk
425 group. Interestingly, the European classification does not include Down syndrome and
426 neurological/-muscular disorder as risk factors for severe COVID-19, while the national
427 classifications consider them as moderate- or high-risk chronic conditions. Several studies
428 have demonstrated an increased risk of COVID-19 hospitalization and death among
429 individuals with Down syndrome [21,22] and multiple sclerosis [23,24]. However, our
430 findings show that only a very small fraction of the discordant population has Down
431 syndrome (≤0.2% in both countries), while those with neurological/muscular disorders make
432 up a larger proportion—23.5% in the Netherlands and 2.3% in Norway. This supports the
433 need to assess the discordant conditions in relation to severe COVID-19 to ensure vaccination
434 prioritization and coverage of individuals at high-risk.

Our study has several limitations. There is a potential underestimation of the population with high- and moderate-risk for severe COVID-19 in the Netherlands. The detection of chronic medical condition categories in the Netherlands relied solely on ICD-10 codes from hospital discharge data. Individuals without recent hospital admission may be missed, as hospital data might not capture those whose conditions are managed in primary care. Consequently, there is a potential underestimation of the number of individuals at moderate- and high-risk. However, the impact on the discordance between the national and the European classifications is likely minimal, as both classifications are based exclusively on ICD-10 codes, irrespective of data source. Conversely, the analyses conducted for the population in Norway, based on diagnostic records from both outpatient and inpatient specialist care, as well as from primary care, were less susceptible to this bias. Another limitation is the absence of ICD-10 codes for asplenia in the Norwegian registries. However, since asplenia is a very rare condition, with 0.44 surgical asplenia per 100,000 person-years in Norway, it is unlikely to affect our overall conclusions [25]. Lastly, the available data did not allow us to assess how well the classifications predict severe COVID-19 outcomes such as hospitalization and death. Due to limited testing capacity in 2020, we could not clearly identify exposed individuals and analyze how their risk is associated with severe COVID-19 outcomes.

Future research should aim to establish a consensus on which chronic medical condition categories are universally recognized as conferring moderate- and high-risk for severe COVID-19. We propose a matched multi-country cohort study to estimate the risk of hospitalization and death due to COVID-19 in individuals with and without specific chronic conditions, accounting for confounders like age, vaccination status, and circulating variants. Additionally, the importance of chronic medical conditions in the hospitalized and deceased

460 populations that are not included in the national and European classifications, and therefore
461 classified as low-risk, should be further assessed. This will help understand which additional
462 conditions should be included in a risk classification for severe COVID-19. The analyses
463 should ideally be conducted at the diagnostic code level, as our findings highlight substantial
464 differences between classifications for specific disease categories. This approach will also
465 help determine whether certain ICD-10 and ICPC-2 codes are overly broad or clinically
466 unsubstantiated. This research will be crucial for deciding which classification most
467 accurately captures the population at highest risk. Moreover, mathematical modeling studies
468 can help to understand the impact of different risk classifications and optimal vaccination
469 strategies [26–29]. Incorporating risk stratification into modeling studies has the potential to
470 design more effective strategies, a consideration often overlooked in current research efforts.
471 Furthermore, exploring emerging data sources and digital health technologies could improve
472 the identification and monitoring of moderate- and high-risk populations.
473

474 # Conclusion

475 There are substantial differences between the European and the respective national medical
476 risk classifications for severe COVID-19 based on pre-existing chronic medical condition
477 categories, which may have important implications for vaccination strategies. The European
478 classification suggests that a larger proportion of the population is at high-risk for severe
479 COVID-19 and may require vaccination. The difference in classification is most pronounced
480 for chronic medical condition categories belonging to the categories of cardiovascular
481 disease, lung disease, and diabetes mellitus. Further research should identify to what extent
482 the discordant chronic conditions are associated with severe COVID-19 risk.
483

Author Contributions

Conceptualization: I Westerhof, G Rozhnova. Data management: I Westerhof, A de Boer. Methodology: I Westerhof, A de Boer, G Rozhnova. Investigation: I Westerhof, A de Boer. Formal analysis: I Westerhof, A de Boer. Visualization: I Westerhof. Writing—original draft: I Westerhof, A de Boer, G Rozhnova. Writing—review and editing: I Westerhof, A de Boer, A Lupattelli, I Slurink, O Boldea, HME Nordeng, JR Bosdriesz, F Pijpers, M Schim van der Loeff, M Knol, JHHM van de Wijgert, P Bruijning, and G Rozhnova.

Declaration of interests

We declare no competing interests.

Acknowledgments

We are grateful to all the participating families in the Netherlands and Norway who are part of the health registries and made this research possible. GR, IW, AdB, and OB were supported by the ZonMw project (10430362220002). GR was supported by Fundação para a Ciência e a Tecnologia project 2022.01448.PTDC, DOI 10.54499/2022.01448.PTDC. GR, IW, AL, and PB were supported by the VERDI project (101045989), funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. IW was supported by the scholarship program iAPOGEE "International Alliance for PharmacoGenetic Epidemiology Excellence" at the University of Oslo, Norway. Data acquisition of the Norwegian data in this study was funded by HN's EU-COVID-19 project, funded by the Norwegian Research Council's COVID-19 Emergency Call (project no.

31270). The work on the Norwegian data was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT) (tsd-drift@usit.uio.no).

Declaration of generative AI in scientific writing

During the preparation of this work the author(s) used Chat GPT in order to improve readability and language. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

References

[1] World Health Organization. Global Covid-19 Vaccination Strategy in a Changing World July 2022 update. 2022.

[2] Antos A, Kwong ML, Balmorez T, Villanueva A, Murakami S. Unusually High Risks of COVID-19 Mortality with Age-Related Comorbidities: An Adjusted Meta-Analysis Method to Improve the Risk Assessment of Mortality Using the Comorbid Mortality Data. Infect Dis Rep 2021;13:700–11. https://doi.org/10.3390/idr13030065.

[3] Zhang J, Dong X, Liu G, Gao Y. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clin Rev Allergy Immunol 2022;64:90–107. https://doi.org/10.1007/s12016-022-08921-5.

[4] Gezondheidsraad. Adviesnota Vaststelling volwassen medische risicogroepen COVID-19-vaccinatiecampagne. 2023.

[5] Norwegian Institute of Public Health. Coronavirus vaccine. Ups-and-Childrenadolescents-with-Underlying-Conditions 2023. https://www.fhi.no/en/id/corona/coronavirus-immunisation-programme/coronavirus-vaccine (accessed April 17, 2024).

[6] European Centre for Disease Prevention and Control. Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza - Version 3.0. 2024.

[7] European Centre for Disease Prevention and Control. Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0. Stockholm: 2021.

[8] Norwegian Institute of Public Health. Coronavirus vaccine 2020. https://www.fhi.no/en/id/corona/coronavirus-immunisation-programme/coronavirus-vaccine (accessed September 1, 2022).

[9] Gezondheidsraad. Advies Strategieën voor COVID-19-vaccinatie. 2020.

[10] World Health Organization. International Statistical Classification of Diseases Related Health Problems 10th Revision Geneva. Https://IcdWhoInt/Browse10/2019/En 2019.

[11] World Health Organization. International Classification of primary care, 2nd edition (ICPC-2). Https://WwwWhoInt/Standards/Classifications/Other-Classifications/International-Classification-of-Primary-Care 2024.

[12] Whittaker R, Toikkanen S, Dean K, Lyngstad TM, Buanes EA, Kløvstad H, et al. A comparison of two registry-based systems for the surveillance of persons hospitalised with COVID-19 in Norway, February 2020 to May 2022. Eurosurveillance 2023;28. https://doi.org/10.2807/1560-7917.ES.2023.28.33.2200888.

[13] Clopper CJ, Pearson ES. The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial. Biometrika 1934;26:404. https://doi.org/10.2307/2331986.

[14] Rijksinstituut voor Volksgezondheid en Milieu. COVID-19 vaccination 2024. https://www.rivm.nl/en/coronavirus-covid-19/vaccination (accessed April 22, 2024).

[15] Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber JT, et al. Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Eurosurveillance 2014;19. https://doi.org/10.2807/1560-7917.ES2014.19.16.20780.

[16] D'Elia L, Giaquinto A, Zarrella AF, Rendina D, Iaccarino Idelson P, Strazzullo P, et al. Hypertension and mortality in SARS-COV-2 infection: A meta-analysis of

observational studies after 2 years of pandemic. Eur J Intern Med 2023;108:28–36. https://doi.org/10.1016/j.ejim.2022.11.018.

[17] Fresán U, Guevara M, Trobajo-Sanmartín C, Burgui C, Ezpeleta C, Castilla J. Hypertension and Related Comorbidities as Potential Risk Factors for COVID-19 Hospitalization and Severity: A Prospective Population-Based Cohort Study. J Clin Med 2021;10:1194. https://doi.org/10.3390/jcm10061194.

[18] Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS One 2021;16:e0258154. https://doi.org/10.1371/journal.pone.0258154.

[19] Wee LE, Tan JYJ, Chiew CJ, Abisheganaden JA, Chotirmall SH, Lye DCB, et al. A Nationwide Cohort Study of Delta and Omicron SARS-CoV-2 Outcomes in Vaccinated Individuals With Chronic Lung Disease. Chest 2024. https://doi.org/10.1016/j.chest.2024.05.017.

[20] Rainer L, Bachner F, Eglau K, Ostermann H, Siebert U, Zuba M. Comorbidities and COVID-19 hospitalization, ICU admission and hospital mortality in Austria. Wien Klin Wochenschr 2022;134:856–67. https://doi.org/10.1007/s00508-022-02036-9.

[21] Bedston S, Almaghrabi F, Patterson L, Agrawal U, Woolford L, Anand SN, et al. Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales. The Lancet Regional Health - Europe 2024;37:100816. https://doi.org/10.1016/j.lanepe.2023.100816.

[22] Semenzato L, Botton J, Drouin J, Cuenot F, Dray-Spira R, Weill A, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. The Lancet Regional Health - Europe 2021;8:100158. https://doi.org/10.1016/j.lanepe.2021.100158.

[23] Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C. Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies. J Neurol 2022;269:1114–20. https://doi.org/10.1007/s00415-021-10803-3.

[24] Moreno-Torres I, Meca Lallana V, Costa-Frossard L, Oreja-Guevara C, Aguirre C, Alba Suárez EM, et al. Risk and outcomes of COVID-19 in patients with multiple sclerosis. Eur J Neurol 2021;28:3712–21. https://doi.org/10.1111/ene.14990.

[25] Orangzeb S, Watle SV, Caugant DA. Adherence to vaccination guidelines of patients with complete splenectomy in Norway, 2008–2020. Vaccine 2023;41:4579–85. https://doi.org/10.1016/j.vaccine.2023.06.034.

[26] Béraud G. Mathematical models and vaccination strategies. Vaccine 2018;36:5366–72. https://doi.org/10.1016/j.vaccine.2017.10.014.

[27] Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science (1979) 2021;371:916–21. https://doi.org/10.1126/science.abe6959.

[28] Viana J, van Dorp CH, Nunes A, Gomes MC, van Boven M, Kretzschmar ME, et al. Controlling the pandemic during the SARS-CoV-2 vaccination rollout. Nat Commun 2021;12:3674. https://doi.org/10.1038/s41467-021-23938-8.

[29] Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first? Sci Adv 2021;7. https://doi.org/10.1126/sciadv.abf1374.



Figure 1. Chronic conditions in the general population. A-B) National and **C-D)** European medical risk classification for severe COVID-19. In all classifications, chronic medical condition categories were assigned if registered in the past six months prior to 1 January 2020, except for cancer which was assigned if registered in the prior five years. The left bars show the number and proportion of each chronic medical condition category in the population. Orange bars indicate the high-risk chronic conditions according to the classification, while blue bars indicate moderate-risk chronic conditions. The dots represent the presence of one or more chronic medical condition categories in an individual, with the upper bars showing the combinations that occur in at least 1% of the general population.



Figure 2. Classification of the general population by risk for severe COVID-19. Population shown as absolute numbers (top) and proportions (bottom) classified by age and risk for severe COVID-19 due to chronic medical condition categories in the **A-B)** national and **C-D)** European classifications.

A The Netherlands; General population

European classification \ National classification	High	Moderate	Low	Total
High	1.3%	**6.4%**	**1.3%**	**9.0%**
Moderate	**0.0%**	0.9%	**0.0%**	**1.0%**
Low	**0.2%**	**4.1%**	85.8%	**90.1%**
Total	**1.5%**	**11.3%**	**87.2%**	100%

Discordance = 12.0% (95%CI 12.0–12.1%)
Concordance = 88.0% (95%CI 87.9–88.0%)

B Norway; General population

European classification \ National classification	High	Moderate	Low	Total
High	2.5%	**6.1%**	**0.7%**	**9.2%**
Moderate	**0.1%**	0.6%	**0.6%**	**1.3%**
Low	**0.4%**	**6.0%**	83.1%	**89.5%**
Total	**3.0%**	**12.7%**	**84.4%**	100%

Discordance = 13.8% (95%CI 13.8–13.9%)
Concordance = 86.2% (95%CI 86.1–86.2%)

C The Netherlands; Hospitalized population

European classification \ National classification	High	Moderate	Low	Total
High	10.0%	**29.4%**	**2.2%**	**41.7%**
Moderate	**0.1%**	2.0%	**0.1%**	**2.3%**
Low	**0.2%**	**4.4%**	51.5%	**56.1%**
Total	**10.3%**	**35.9%**	**53.8%**	100%

Discordance = 36.5% (95%CI 36.0–37.0%)
Concordance = 63.5% (95%CI 63.0–64.0%)

D Norway; Hospitalized population

European classification \ National classification	High	Moderate	Low	Total
High	11.0%	**19.8%**	**1.7%**	**32.5%**
Moderate	**0.5%**	1.3%	**1.3%**	**3.2%**
Low	**0.8%**	**14.1%**	49.5%	**64.3%**
Total	**12.2%**	**35.3%**	**52.5%**	100%

Discordance = 38.2% (95%CI 36.2–40.3%)
Concordance = 61.8% (95%CI 59.7–63.8%)

E The Netherlands; Deceased population

European classification \ National classification	High	Moderate	Low	Total
High	10.4%	**40.6%**	**2.4%**	**53.4%**
Moderate	**0.1%**	2.7%	**0.1%**	**2.9%**
Low	**0.1%**	**3.4%**	40.2%	**43.7%**
Total	**10.6%**	**46.7%**	**42.7%**	100%

Discordance = 46.6% (95%CI 45.5–47.5%)
Concordance = 53.4% (95%CI 52.5–54.5%)

F Norway; Deceased population

European classification \ National classification	High	Moderate	Low	Total
High	16.0%	**28.0%**	**1.2%**	**45.1%**
Moderate	**0.6%**	2.7%	**1.4%**	**4.7%**
Low	**1.0%**	**13.0%**	36.2%	**50.2%**
Total	**17.5%**	**43.8%**	**38.7%**	100%

Discordance = 45.1% (95%CI 40.8–49.6%)
Concordance = 54.9% (95%CI 50.4–59.2%)

Figure 3. Discordance in assigning risk status to individuals between the European and national classifications in the A-B) general population, **C-D)** hospitalized population, and **E-F)** deceased population. The discordance between the European and each national classification was calculated as the proportion of the general populations with a different risk status (off-diagonal elements). Concordance is the proportion of the population classified into the same risk group (diagonal elements). Since every individual belongs to one of the risk groups, the elements of the matrix plots add up to 100%.



Figure 4. Chronic conditions in the discordant general population. A-B) National and **C-D)** European medical risk classification for severe COVID-19. In all classifications, chronic medical condition categories were those that had been registered in the past six months prior to 1 January 2020, except for cancer which was included as a chronic medical condition if registered in the past five years preceding 1 January, 2020. The dots represent the presence of one or more chronic medical condition categories. The left bars show the number and proportion of each chronic medical condition category in the population. Orange bars indicate the high-risk chronic conditions according to the classification, while blue bars indicate moderate-risk chronic conditions. The upper bars show the combinations of chronic conditions that occur in at least 1% of the discordant general population.